

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

July 17, 2017

Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, P.J. Towers,  
Dalal Street, Mumbai – 400001


**Subject:** Statement of Investor Complaints Under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter Ended 30<sup>th</sup> June, 2017 (**Scrip Code: 956084**)

Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Statement of Investor Complaints of **Genlink Pharma Solutions Private Limited** (Scrip code: **956084**) for quarter ended 30<sup>th</sup> June, 2017.

Please take the same on your records.

Thanking you,

For **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**



**ANAND PRAFULCHANDRA SHAH**

(Director)

DIN:00597145

ADD:1704, Kesar Solitaire, Plot No. 5,  
Sector 19, Sanpada, NaviMumbai - 400705,  
Maharashtra, India

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)


Statement of Investor Complaints under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for quarter ended 30<sup>th</sup> June, 2017.

Particulars	Number
No. of Investor Complaints Pending at the Beginning of quarter i.e. on 10 <sup>th</sup> April, 2017	Nil
No. of Investor Complaints received during the quarter	Nil
No. of Investor Complaints disposed off during the quarter	Nil
No. of Investor Complaints those remaining unresolved at the end of the quarter i.e. on 30 <sup>th</sup> June, 2017	Nil

Kindly take the Note of the same

Thanking you,

For GENLINK PHARMA SOLUTIONS PRIVATE LIMITED



ANAND PRAFULCHANDRA SHAH  
(Director)

DIN:00597145

ADD:1704, Kesar Solitaire, Plot No. 5,  
Sector 19, Sanpada, NaviMumbai - 400705,  
Maharashtra, India